Health
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
TOKYO & BASKING RIDGE, N.J., December 22, 2025--ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/dc1634dba7acf4590ec4f2597c725c82"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fH_h5ekQZVYZe4hMdr3amQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dc1634dba7acf4590ec4f2597c725c82","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Tenth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast05 phase 3 trial results","length":147,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Sixteenth Breakthrough Therapy Designation granted by the FDA across the oncology portfolio of Daiichi Sankyo","length":109,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":256,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., December 22, 2025--(BUSINESS WIRE)--ENHERTU® (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for adult patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.","length":366,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":229,"tagName":"p"},{"type":"text","content":"The U.S. Food and Drug Administration (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. The medicine needs to have shown encouraging preliminary clinical results that demonstrate substantial improvement on a clinically significant endpoint over available medicines.","length":409,"tagName":"p"},{"type":"text","content":"The FDA granted this BTD based on results from the DESTINY-Breast05 phase 3 trial presented in Presidential Symposium I at the 2025 European Society of Medical Oncology (#ESMO25) Congress a...